The Pfizer Oncology Pipeline: An Overview

Pfizer’s oncology pipeline has grown into one of the broadest in the pharmaceutical industry, spanning antibody-drug conjugates, targeted small molecules, bispecific antibodies, and early-stage platforms like mRNA cancer vaccines. The company’s $43 billion acquisition of Seagen in 2023 was the clearest signal of its strategic direction, adding a portfolio of approved and investigational antibody-drug conjugates to an already expanding roster of cancer therapies. What makes the pipeline worth understanding now is the sheer variety of mechanisms being pursued across tumor types, from breast cancer to blood cancers to hard-to-treat colorectal disease.

The ADC Strategy After Seagen

Antibody-drug conjugates, or ADCs, are engineered molecules that combine an antibody designed to find cancer cells with a potent cell-killing drug attached by a chemical linker. The antibody acts as a delivery vehicle, bringing the toxic payload directly to the tumor and sparing more of the healthy tissue that traditional chemotherapy would damage. Pfizer’s bet on this technology became explicit with the Seagen acquisition, which brought three approved ADCs into its portfolio: enfortumab vedotin, tisotumab vedotin, and brentuximab vedotin.

Enfortumab vedotin, marketed as Padcev, targets Nectin-4 on the surface of urothelial (bladder) cancer cells. In a landmark trial comparing the drug in combination with pembrolizumab against standard chemotherapy in patients with untreated advanced urothelial cancer, median overall survival roughly doubled, from about 16 months with chemotherapy to about 31.5 months with the combination.¹ A meta-analysis pooling data from multiple studies found the combination achieved an overall response rate of about 68% and a one-year survival rate of roughly 79%.² The two drugs are thought to work sequentially rather than synergistically: the ADC damages tumor cells, exposing antigens that help the immune checkpoint inhibitor mount a stronger attack.³

Tisotumab vedotin targets tissue factor, a protein overexpressed in several solid tumors, and has been studied most extensively in recurrent cervical cancer. In a randomized trial comparing it to investigator’s choice of chemotherapy as a second- or third-line treatment, tisotumab vedotin reduced the risk of death by 30%, with median overall survival improving from 9.5 months to 11.5 months.⁴ A broader meta-analysis of single-arm studies estimated a median overall survival of nearly 12 months, with an overall response rate of about 30%, though the rate of grade 3 or higher side effects was high at roughly 62%.⁵ For a cancer with limited options after initial treatment fails, those gains matter, even if the toxicity profile demands careful management.

Brentuximab vedotin, the oldest ADC in the portfolio, targets CD30 on Hodgkin lymphoma cells. The ECHELON-1 trial established it as a first-line option when combined with chemotherapy: at six years of follow-up, overall survival was about 94% with the brentuximab combination compared to roughly 89% with the standard regimen, and fewer patients needed subsequent treatments like transplantation.⁶ That said, the drug’s benefits do not appear to extend to every setting. A randomized phase 2 study adding brentuximab to high-dose chemotherapy before stem cell transplant was stopped early for futility, with no improvement in disease-free survival, suggesting that prior exposure to the drug and the specific treatment context can limit its usefulness.⁷

New Approaches in Breast Cancer

Pfizer’s breast cancer pipeline goes beyond the familiar CDK4/6 inhibitor class that includes palbociclib (Ibrance). While palbociclib transformed treatment for hormone receptor-positive breast cancer, resistance develops over time. Common mechanisms include loss of the Rb protein, amplification of other cell-cycle drivers, and activation of upstream growth signals.⁸ That reality has pushed the company toward two distinct strategies: refining CDK4 inhibition itself and developing drugs against entirely new targets.

Atirmociclib is Pfizer’s selective CDK4 inhibitor, designed to block only CDK4 while leaving CDK6 alone. Current approved drugs like palbociclib hit both CDK4 and CDK6, and the CDK6 inhibition is thought to contribute to the severe drops in white blood cell counts (neutropenia) that commonly limit dosing. In preclinical testing, atirmociclib showed greater inhibition of CDK4-driven cell signaling and superior tumor growth inhibition compared to palbociclib at its recommended dose.⁹ Whether those preclinical advantages translate to better clinical outcomes remains to be seen, but the rationale is straightforward: more targeted inhibition could allow higher effective doses with fewer blood-count-related side effects.

The more novel breast cancer program involves PF-07248144, a first-in-class inhibitor of KAT6A and KAT6B, enzymes that regulate gene activity through a process called histone acetylation. In a phase 1 study enrolling heavily pretreated patients with estrogen receptor-positive, HER2-negative metastatic breast cancer, the drug combined with fulvestrant achieved an overall response rate of about 30% and a median progression-free survival of roughly 10.7 months.¹⁰ Those numbers are noteworthy because this population had already cycled through multiple prior therapies. Updated dose-optimization data showed that the higher dose (5 mg daily) yielded a response rate closer to 37% with a median duration of response exceeding 15 months, while a lower dose still achieved meaningful activity at about a 24% response rate.¹¹ These results represent the first clinical proof that KAT6 is a viable drug target in cancer, opening a mechanism of action that has no approved competitors.

The PARP-Plus Combination in Prostate Cancer

Talazoparib, a PARP inhibitor originally approved for certain breast cancers, has become a cornerstone of Pfizer’s prostate cancer strategy through its combination with enzalutamide. PARP inhibitors work by blocking a DNA repair pathway that cancer cells with certain genetic defects (particularly in homologous recombination repair genes like BRCA1/2) depend on for survival. Combining PARP inhibition with hormonal therapy aims to attack the cancer on two fronts simultaneously.

The TALAPRO-2 trial tested talazoparib plus enzalutamide against enzalutamide alone as a first-line treatment for metastatic castration-resistant prostate cancer. The combination significantly delayed disease progression across the full study population.¹² In the subset of patients whose tumors carried DNA repair defects, the effect was even more pronounced, with a radiographic progression-free survival hazard ratio of 0.45, meaning the combination cut the risk of progression or death by more than half compared to enzalutamide alone.¹³

The final overall survival analysis, reported after a median follow-up of over four years, confirmed the combination’s benefit: patients receiving talazoparib plus enzalutamide lived a median of about 46 months compared to 37 months with enzalutamide alone, a statistically significant improvement.¹⁴ This nearly nine-month survival gain solidified the combination as a standard-of-care option, particularly for the molecularly defined group with DNA repair deficiencies.

Lorlatinib in ALK-Positive Lung Cancer

Lorlatinib (Lorbrena) targets ALK-rearranged non-small-cell lung cancer, a subtype that accounts for a small but significant fraction of lung cancer cases, particularly in younger patients who have never smoked. What sets lorlatinib apart from earlier ALK inhibitors is its ability to cross the blood-brain barrier and control cancer that has spread to the central nervous system, a common and devastating complication in this disease.

The phase 3 CROWN study compared lorlatinib to crizotinib, the original ALK inhibitor, as first-line treatment. At five years of follow-up, the results were striking: median progression-free survival had still not been reached with lorlatinib, compared to just 9.1 months with crizotinib, and roughly 60% of lorlatinib-treated patients remained progression-free at five years versus 8% on crizotinib.¹⁵ The intracranial control was equally dramatic. Among patients who had measurable brain metastases at the start of treatment, 82% responded to lorlatinib compared to 23% on crizotinib, with 71% of lorlatinib-treated patients achieving a complete intracranial response.¹⁶

A post hoc analysis from the CROWN trial further detailed the drug’s brain activity. The 12-month cumulative incidence of brain progression was just 7% with lorlatinib versus 72% with crizotinib in patients who already had brain metastases, and only 1% versus 18% in those without brain involvement at baseline.¹⁷ For patients with an ALK-driven cancer, the fear of brain metastases is often as pressing as the primary disease itself, and lorlatinib addresses that fear more effectively than any predecessor.

Pfizer is also pushing into BRAF-mutant non-small-cell lung cancer through the encorafenib-binimetinib combination. In treatment-naive patients, the disease control rate at 24 weeks was about 64%, while previously treated patients had a median progression-free survival of about 9.3 months.¹⁸ BRAF mutations are rarer in lung cancer than in melanoma or colorectal cancer, but the patients who have them had limited targeted options until recently.

BRAF-Mutant Colorectal Cancer

Roughly 8 to 12% of metastatic colorectal cancers harbor a BRAF V600E mutation, and historically these tumors have responded poorly to standard chemotherapy. Pfizer’s encorafenib, a BRAF inhibitor acquired through Array BioPharma, has become central to treating this subgroup. The earlier BEACON study established the combination of encorafenib and cetuximab (an anti-EGFR antibody) as a second-line standard of care, with median overall survival of about 9.3 months for the doublet and a confirmed response rate of roughly 20%, far exceeding the 2% response rate seen with conventional treatment.¹⁹

The more recent BREAKWATER trial has moved this combination into the first-line setting, adding chemotherapy (mFOLFOX6) to encorafenib and cetuximab. Results were dramatic: median progression-free survival was about 12.8 months versus 7.1 months with standard treatment, and an interim analysis showed median overall survival of roughly 30.3 months compared to 15.1 months, essentially doubling it.²⁰ The confirmed objective response rate was about 61% in the combination arm versus 40% with standard care, with a median duration of response approaching 14 months.²¹ These results represent a genuine transformation in outcomes for a group of patients who previously had among the worst prognoses in colorectal cancer.

Elranatamab for Multiple Myeloma

Elranatamab is Pfizer’s bispecific antibody for relapsed or refractory multiple myeloma. It works by simultaneously binding BCMA on the surface of myeloma cells and CD3 on T cells, physically bridging the two so the immune cell can destroy the cancer cell. This is fundamentally different from the ADC approach: rather than delivering a toxic drug, bispecifics redirect the patient’s own immune system.

The MagnetisMM-3 trial enrolled patients whose myeloma had returned after multiple prior treatments but who had not previously received BCMA-directed therapy. The primary endpoint was met, with about 61% of patients achieving an objective response. Over 35% achieved a complete response or better, and among patients who could be evaluated for minimal residual disease, 92% tested negative at a deep sensitivity threshold.²² With extended follow-up, the median duration of response had not yet been reached, and the 12-month duration of response rate was about 74%, suggesting that when patients do respond, the benefit tends to last.²³

A practical advantage of elranatamab is its dosing flexibility. After six cycles of weekly subcutaneous injections, patients who maintained their response could switch to every-other-week dosing. Among the 50 patients who made that switch, 80% either improved or maintained their response for at least six months.²⁴ For patients living with a chronic relapsing cancer, fewer clinic visits for treatment can make a real difference in quality of life.

Next-Generation Molecules and Early-Stage Programs

Beyond the drugs in late-stage trials, Pfizer’s early pipeline includes several programs that represent different bets on where oncology is heading. One is PF-08046876, a next-generation ADC targeting integrin beta-6, a protein expressed on certain solid tumors. What distinguishes it from earlier ADCs is its payload: a camptothecin-class drug that has been engineered for stronger bystander killing (meaning it can damage neighboring cancer cells that do not themselves express the target) and for reduced susceptibility to multidrug resistance pumps that cancer cells often use to eject chemotherapy drugs.²⁵ If drug efflux is a major reason ADCs stop working in some patients, designing around that problem from the outset could extend the durability of responses.

Pfizer has also explored bispecific molecules that direct T cells against solid tumors. PF-06671008, an early-stage molecule targeting P-cadherin through a CD3-engaging bispecific design, showed regression of established tumors in mouse models, with evidence of T cell activation, tumor infiltration, and direct killing as the mechanism.²⁶ Moving bispecific antibodies from blood cancers (where they have had clear success) into solid tumors has proven far more difficult across the industry, because solid tumors create a hostile microenvironment that suppresses immune cell activity. Preclinical successes in this space are common; clinical translations are not. Whether Pfizer can bridge that gap with P-cadherin or similar targets remains an open question.

The mRNA cancer vaccine space is another area where Pfizer has signaled interest, building on the mRNA manufacturing infrastructure established during COVID-19. Unlike prophylactic vaccines that prevent infection, cancer mRNA vaccines are therapeutic: they encode tumor-specific antigens and are designed to train a patient’s immune system to recognize and attack cells displaying those antigens.²⁷ Personalized cancer vaccines, in which each patient’s vaccine is custom-built from their tumor’s unique mutational profile, are in early-phase testing across the industry. The appeal is obvious, but the manufacturing complexity and regulatory pathway for individualized products are formidable.

The Cost Problem in Oncology Combinations

One challenge that cuts across the entire oncology pipeline, for Pfizer and every other company, is cost. The trend in cancer treatment is toward combinations: an ADC with a checkpoint inhibitor, a PARP inhibitor with hormonal therapy, a BRAF inhibitor with an EGFR antibody and chemotherapy. Each drug in the combination carries its own price tag, and the totals add up quickly. An analysis of combination therapies for advanced endometrial cancer found that acquisition costs per patient exceeded $280,000 for dostarlimab plus chemotherapy and $217,000 for pembrolizumab plus lenvatinib, with neither combination meeting a standard cost-effectiveness threshold of $100,000 per life-year gained.²⁸

Similar dynamics appear in melanoma, where a cost-benefit model comparing two combination regimens found that the cost per month of progression-free survival ranged from roughly $17,700 to $22,200, and the cost per responding patient ranged from about $282,000 to $389,000.²⁹ These figures are not specific to Pfizer’s drugs, but they illustrate the broader tension: the same clinical trial successes that expand treatment options also raise questions about who can afford them. As Pfizer’s pipeline generates more combination regimens with survival benefits measured in months rather than years, the pressure to demonstrate value beyond raw efficacy data is only going to intensify.